🇺🇸

US SEC Filing Intelligence

· daily

US Corporate Distress Financial Stress SEC Filings — May 06, 2026

Across 43 filings in the USA Corporate Distress & Bankruptcy stream, financing activities dominate with 25+ companies announcing debt issuances, credit amendments, or equity offerings to enhance liquidity, refinance maturities, or fund growth, signaling proactive balance sheet management amid neutral-to-positive sentiments rather than outright distress. Period-over-period trends show mixed earnings: 6/10 reporting companies posted revenue growth (avg +12% YoY, e.g., Solstice +10%, Texas Pacific +21%), but margins compressed in 4/6 (avg -150 bps, e.g., Solstice -277 bps EBITDA margin), with EBITDA flat/declining in several despite sales beats. Capital allocation leans toward shareholder returns (dividends declared by Solstice, Texas Pacific, Carriage) and buybacks/repurchases (Maplebear $349M, Alkami $100M authorized), while forward guidances are mostly reaffirmed or provided positively (Solstice FY26 sales $3.9-4.1B, Maplebear Q2 GTV +11-13%). True distress signals are sparse (1 delisting notice, 1 payables advance, 1 goodwill impairment), but outliers like Sadot's Nasdaq issues and MSP Recovery's restructuring aid highlight pockets of vulnerability. Sector patterns emerge in energy/real estate (facility expansions, e.g., Permian $3B credit) and tech/pharma (financings for commercialization). Implications: Low systemic distress but watch liquidity-dependent firms; opportunities in refinancings enabling M&A/growth.

43 high priority 43 total filings
· daily

US Executive Officer Management Changes SEC — May 06, 2026

Across 34 filings in the USA Executive & Director Changes stream (May 6, 2026), leadership transitions dominate with 18 CEO/CFO/COO promotions or appointments (e.g., Orrstown, General Mills, Birchtech), 10 departures/retirements (e.g., Anavex CEO, Energy Recovery CEO/CFO), and 6 annual meetings with strong director election support (avg 95%+ for/approval). Period-over-period trends show mixed financials where disclosed: Energy Recovery revenue +20% YoY but gross margins -2750 bps to 27.8%; eHealth revenue -22% YoY but Medicare margins +700 bps to 41%; no broad insider trading but capital allocation positives like Energy Recovery's $25M buyback and Carvana's 1:5 split. Positive sentiment in 12/34 (35%) centers on experienced hires/promotions enhancing strategy (e.g., Hamilton Insurance, Wiley AI focus), while mixed/negative in 7/34 flag risks from sudden exits (Regenerex CFO termination, Anavex CEO departure with 10-Q delay). Portfolio-level pattern: orderly transitions signal continuity in financials/insurance (e.g., Orrstown, RenaissRe), but biotech/healthcare shows churn (Anavex, Bionano, Actuate with going concern). Implications: Bullish for stable firms with internal promotions; monitor biotech for disruption risks amid M&A/innovation catalysts.

34 high priority 34 total filings
· daily

US Corporate Board Director Changes SEC Filings — May 06, 2026

Across 34 filings from May 6, 2026, USA boardroom changes reveal high executive turnover with 12 CEO/CFO transitions (7 appointments, 5 departures), predominantly neutral sentiment (18/34) but tilting positive in financials/insurance (e.g., 95%+ AGM approvals in 6 cases). Period-over-period trends show mixed financial health: revenue growth in 4 firms (Energy Recovery +20% YoY, OEM +65%; eHealth Medicare margins +700bps despite -22% rev; Flutter FY25 +17%) contrasted by sharp declines (Energy Recovery gross margins -2750bps, eHealth net loss widening). Critical developments include sudden CFO terminations/suspensions (Regenerex, Bright Mountain) and interim leadership in biotechs (Anavex, Bionano), signaling potential governance risks amid 3 10-Q extensions/delays. Portfolio-level patterns: Planned retirements/successions (8 cases) outnumber contentious exits (4), with strong shareholder support at AGMs (avg 95%+ approval rates); insurance/financial sectors show board strengthening via experienced adds, while biotechs face leadership voids amid cash concerns. Capital allocation leans retention-focused (e.g., Energy Recovery $25M buyback, comp hikes), but M&A/integration ties (Flora, International Endeavors) flag strategic shifts. Implications: Opportunities in stable transitions, risks in interim-heavy biotechs.

34 high priority 34 total filings
· daily

US Merger & Acquisition SEC Filings — May 06, 2026

The 15 filings reveal a surge in SPAC activity with multiple IPOs (Plutonian $100M, Quantum Leap $200M), unit separations, and deadline extensions (GP-Act III to Nov 2026, Legato to Aug 2026), signaling robust blank check company fundraising amid M&A appetite. Key M&A/takeover highlights include Broadwind's $19.5M facility sale and pivot to precision manufacturing, 908 Devices' NIRLAB acquisition with raised FY2026 revenue guidance to $67-70M (19-25% growth), Nuveen Churchill funds' $347M asset swap, and Brookfield's $1.2B takeover of Peakstone Realty Trust. Period-over-period trends show revenue growth in operating companies (908 Devices +14% YoY to $13.4M, Ascent +9% YoY to $19.4M) but margin pressures (Ascent -272bps to 14.5%, 908 gross +400bps to 51% offset by wider $12M net loss). Mixed sentiments dominate earnings/divestitures, with SPACs neutral-to-positive and compliance risks emerging. Portfolio-level pattern: 7/15 filings involve SPAC lifecycle events, 5 M&A transactions, indicating heightened US takeover activity but with execution risks like high redemptions and guidance withdrawals.

15 high priority 15 total filings
· monthly

US Pre-Market SEC Filings Roundup — May 06, 2026

Overnight SEC filings reveal mixed Q1 2026 earnings across 20+ companies, with healthcare/biotech (e.g., BeOne +35% YoY rev, LivaNova +14.3%) and services (Clear Secure +19.7%, Taboola +9.1%) showing robust revenue growth averaging +15% YoY, while building products (Owens Corning -10%, LP -21%) face sharp declines amid volume/price pressures. Margin trends are divergent: expansions in high-growth names (+720 bps at Clear) contrast compression (-600 bps avg in building materials). M&A momentum builds with Two Harbors CCM deal at 14% premium (meeting May 19), Skyworks-Qorvo Phase II review, and Woori share exchange; SPACs like Quantum Leap ($200M IPO) signal capital inflow. 15+ 13F filings highlight institutional tech overweight (NVIDIA top in 8/15, avg $100M+ positions), implying conviction. Capital returns strong: 10+ dividends declared (e.g., Acushnet $0.255, Deluxe $0.30), buybacks (Life Time $62M, Acushnet $10M). Guidance raised in 8/15 reporters (e.g., BeOne to $6.3-6.5B), cut in 3 (Amcor FCF down), setting Q2 catalysts. Portfolio implication: Rotate from cyclicals to healthcare/tech/services ahead of market open.

18 high priority 32 medium 50 total filings
· daily

Biotech Small-Cap Approvals — May 05, 2026

The May 05, 2026 period captured five 'Other' category (FALLBACK) approvals with neutral investment signals (all strength 5/10, materiality 5/10), comprising 0 NMEs, 0 biosimilars, 0 label expansions per mix breakdown despite individual summaries using 'biosimilar' terminology—suggesting small-molecule generic ANDA approvals. No dominant therapeutic area theme emerges, with products spanning cardiovascular (Propranolol Hydrochloride by IPCA LABS LTD), rheumatology/oncology (Methotrexate Sodium by HETERO LABS LTD VI), ophthalmology (Fluorescein Sodium by BPI LABS), neurology (Pregabalin by UNICHEM), and rare metabolic disorders (Glycerol Phenylbutyrate by LUPIN). Highest-conviction signal is LUPIN's Glycerol Phenylbutyrate approval, a neutral entrant into a narrow rare disease market with undisclosed commercial metrics and no exclusivity details. Key risk/watch item: competitive erosion for originators of these mature molecules and lack of disclosed peak sales/pricing data limits upside assessment.

5 total filings
· daily

Contract Option Exercises — May 05, 2026

A single $242,713,808 option exercise was recorded for FCN, INC. from the Department of the Treasury's IRS IT Strategy and Modernization office, representing a 100% civilian award with zero defense exposure. This firm fixed price delivery order for Broadcom software license and maintenance services underscores IRS prioritization of IT modernization, with $240,260,396 already outlayed signaling strong execution by the Rockville, MD-based woman-owned small business. The highest-conviction bullish signal is FCN, INC.'s full and open competition win on a contract with $454,642,987 potential including options, implying rapid revenue scaling from an estimated $60M annual base. Key watch item is high contract pricing risk under firm fixed price terms amid the current performance period ending November 30, 2026.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — May 05, 2026

The single mega contract in this period totals $242,713,808 in obligations, entirely civilian with zero defense exposure, centered on IRS IT Strategy and Modernization via a firm fixed price delivery order to FCN, INC. FCN, INC., a woman-owned small business, secured this full and open competition win for Broadcom software licenses and maintenance, with $240,260,396 already outlayed signaling strong execution amid a current performance period ending November 30, 2026. The highest-conviction bullish signal is FCN's rapid progress on this $242M obligation (potential $454M with options), highlighting competitive strength in IT application support. A key risk is high pricing/execution risk inherent to the firm fixed price structure, with investors watching option exercises and outlay progress beyond $240M.

1 total filings
· daily

S&P 500 Financials Sector SEC Filings — May 05, 2026

Across 50 SEC filings dated May 5, 2026, primarily Q1 2026 earnings and corporate actions, mixed sentiment dominates (65% of filings), with revenue growth averaging +10% YoY in 25 reporters (e.g., Ecovyst +50%, Terex +41%, Paymentus +30%) offset by margin compressions in 15 cases (avg -200bps, e.g., Atkore -780bps) due to costs, impairments, and one-offs. Financials subset (e.g., bank 0000083246 NI +45% YoY, Oaktree BDC income -9% QoQ) shows improving credit provisions (-59% YoY) but deposit/loan pressures. Capital allocation prioritizes returns: $1.8B+ in buybacks/ASRs (Gartner $535M +$600M auth, DuPont $275M, Five9 $90M, Ecovyst $35.7M) and dividends (e.g., Atkore $0.33, Fresh Del Monte $0.30). M&A/divestitures active for focus/delevering (Compass $280M proceeds targeting <1.0x leverage, Helix $107.5M sale, Expro $215M acq). Guidance raised in 8/15 cases (DuPont EPS $2.35-2.40, ADM $4.15-4.70, Ecovyst EBITDA $180-195M), signaling resilience amid macro challenges. SPAC IPOs (CH4 $200M, ARC $105M) highlight M&A appetite. Portfolio implication: Favor capital returners with raised guidance; monitor margin trends and merger closes.

17 high priority 33 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — May 05, 2026

Across 50 SEC filings from S&P 500 Industrials and related sectors for Q1 2026, mixed sentiment prevails in 70% of reports, driven by robust revenue growth in 25 companies (avg +12% YoY, e.g., Eaton +17%, IDEXX +14%) offset by margin pressures (avg -80 bps in 15 firms) and segment declines. Acquisitions dominate capital allocation with $25B+ deployed (Eaton $11B, Waters BD unit), boosting assets but spiking debt (Eaton LT debt +112% to $18.5B). Guidance raised in 12 firms (e.g., Eaton organic 9-11%, Waters rev $6.4-6.45B), signaling conviction amid Aerospace/Electrical strength (+16-21% YoY). Dividend hikes (Sunoco +6.25%, Ferguson $0.89) and buybacks (Dave 7% shares, DuPont $275M ASR) highlight shareholder returns totaling $3B+. Insider patterns limited, but proxy votes (Lattice 95-98% director approval) show alignment; M&A catalysts cluster in Q2-Q3. Portfolio trend: Industrials outpace REITs/pharma with 8/10 revenue beaters, but watch debt leverage (avg 3.5x up 20% YoY in acquirers). Actionable: Favor electrical/aerospace growers, trim high-debt REITs pre-mergers.

9 high priority 41 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — May 05, 2026

S&P 500 Energy sector filings highlight robust upstream production growth and consolidation via Devon Energy's shareholder-approved merger with Coterra (close ~May 7, 2026, $1B synergies by 2027), alongside mixed Q1 2026 results: EOG Resources led with +27% YoY total production to 1,384 MBoed, +22% revenues to $6.9B, and +30% CFO to $3.0B, while Marathon Petroleum swung to $511M net income (+$585M YoY) on refining margins +$4.36/bbl to $17.74 but midstream EBITDA -7% to $1.6B. Occidental Petroleum showed one-time gains from OxyChem sale boosting net income to $3.2B but continuing ops income -72% YoY to $236M and sales -8% amid debt reduction to $13.3B toward $10B target. Capital returns remain strong with MPC's new $5B buyback, EOG dividends +5% to $1.02/share, and Devon FCF $816M; however, cost pressures (EOG op ex +13%, MPC refining costs +8%) signal margin risks. Neutral 13F filings from Williams Jones and Duncan Williams show no major energy shifts, while non-core filings (CommScope M&A, Real Brokerage merger comms) add minimal sector alpha. Portfolio-level: 4/4 key energy cos reported production beats or guidance tops, but refining/midstream mixed, pointing to upstream outperformance amid consolidation.

5 high priority 8 medium 13 total filings
· daily

US SEC Filings Daily Market Digest — May 05, 2026

Across 50 SEC filings for May 5, 2026, Q1 2026 earnings dominate with mixed sentiment prevailing in 70% of reports, featuring revenue growth in 12 companies (avg +15% YoY) offset by margin compression in 8 (avg -150 bps) amid input costs, FX, and one-offs. Industrials and chemicals shine with beats/raises (DuPont +15% EBITDA, Ecovyst +87%), while energy sees M&A catalysts like Coterra-Devon merger closing May 7. Capital allocation leans bullish with $2.5B+ in repurchases/dividends announced (Gartner $535M, Five9 $90M ASR), but biotech/fintech show losses widening (Eve +41% net loss, IDEAYA +18%). Divestitures (DuPont Aramids $1.2B, Compass Sterno $292.5M) signal portfolio optimization, and SPAC IPOs (CH4 $200M, ARC $105M) indicate deal appetite. Portfolio trend: 6/10 firms raised FY2026 guidance, signaling resilience; watch margin trends and energy consolidation for alpha.

16 high priority 34 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — May 05, 2026

Across 12 DEF 14A proxy filings dated around May 5, 2026, overarching themes include routine annual meetings for director elections (9/12), auditor ratifications (10/12), say-on-pay advisory votes (5/12), and equity incentive plan approvals, alongside special actions like share increases (Orgenesis, FibroBiologics), SPAC deadline extensions (Range Capital), reverse stock splits (Beyond Air), and reincorporations (Sonoma). Key period-over-period trends: CrowdStrike's FY2026 revenue +22% YoY to $4.81B, ARR +24% YoY to $5.25B, FCF margin 26%; FONAR exec comp down 21% YoY for CEO to $295k while flat for another; Range Capital trust +5.6% to $121.9M from post-IPO $115.6M. Critical developments: delisting risks (Beyond Air), dilution proposals (4/12 filings), and strong governance signals (Workday). Market implications: heightened dilution risks in biotechs/SPACs signal bearish near-term pressure, while SaaS leaders like CrowdStrike show portfolio-level growth outperformance; neutral sentiment dominates (8/12), but vote outcomes could drive volatility ahead of summer meetings.

12 high priority 12 total filings
· daily

US IPO Pipeline SEC S-1 Filings — May 05, 2026

Two S-4 filings on May 05, 2026, underscore active merger-driven paths in the US IPO pipeline, with ATII Holdings advancing a SPAC business combination between Forge Nano Inc. and Archimedes Tech SPAC Partners II Co., while Mountain Holding (New Equitable) pursues consolidation of Corebridge Financial ($385B AUM) and Equitable Holdings (>$1.1T AUM) into a new NYSE-listed EQH entity. Period-over-period data reveals stable customer concentration at ATII (two major revenue customers in 2025 vs. two in 2024), indicating revenue reliability but no broader growth metrics available across filings. Critical developments include ATII's lock-up expiration today (2026-05-05) for sponsors, insiders, and Forge Nano holders, and Mountain's targeted merger close by year-end 2026 pending multi-regulator approvals. Neutral sentiment at ATII contrasts with mixed at Mountain due to execution risks detailed from page 44. Portfolio-level patterns highlight merger/SPAC reliance for public access, with scale in financials (> $1.485T combined AUM) but regulatory hurdles prevalent. Market implications favor monitoring unlock volatility and approval catalysts for near-term trading alpha.

2 high priority 2 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — May 05, 2026

Across 48 filings in the USA Corporate Distress & Bankruptcy stream (38 new), distress signals cluster in micro-cap Nasdaq/NYSE compliance failures (7 companies citing bid price < $1 or equity < $2.5M), plant closures, and widening losses (e.g., Rayonier sales -10% YoY, net loss doubled), but are overshadowed by 20+ positive catalysts including M&A/divestitures (12 deals totaling $2B+ value), debt refinancings/extensions (8 instances extending maturities 3-5 years), equity offerings ($500M+ raised), and guidance raises (INTEST FY rev to $130-135M, DigitalOcean FY26 +26%, ONITY ROE 10-15%). Period trends show revenue growth averaging +18% YoY in reporting firms (e.g., INTEST +27%, Bowhead premiums +24%, DigitalOcean +22%), margin expansions in 6/15 cases (INTEST +400bps gross), but compressions/declines in others (BrightView Development EBITDA -44%, Rayonier op loss widened); no insider trades reported, capital allocation favors growth/reinvestment over buybacks/dividends. Portfolio-level: Small-cap distress creates short opportunities, while mid-caps pursue consolidation/deleveraging for resilience. Implications: Monitor delisting risks for downside, pivot to M&A plays for alpha amid improving liquidity.

48 high priority 48 total filings
· daily

US Executive Officer Management Changes SEC — May 05, 2026

Across 36 filings in the USA Executive & Director Changes stream, a dominant theme is high executive turnover, particularly in finance roles (CFOs, controllers, accounting officers in 12 companies including Atlantic American, Kimberly-Clark, Core Scientific, CF Industries, Genesco, Portillo's), with 18 appointments and 14 departures, often neutral but featuring experienced hires signaling continuity. Embedded Q1/FY2026 earnings show mixed revenue trends (avg +3.5% YoY across 15 reporting firms, but declines in 7 like Energizer -3%, FTC Solar -17%, Primoris -5.4%), offset by margin expansions (e.g., Energizer +360bps, Emerson +320bps) and reaffirmed/raised guidance in 10 cases. Positive sentiments dominate leadership adds (e.g., Integra, iAnthus, CF Industries), while negatives cluster around disputes (B&G Foods). Portfolio-level: Margin resilience amid soft volumes; capital returns strong ($500M Klaviyo buyback, $2.2B Emerson). Implications: Opportunities in experienced leadership turnarounds, risks in finance churn; watch catalysts like earnings calls.

36 high priority 36 total filings
· daily

US Corporate Board Director Changes SEC Filings — May 05, 2026

The 35 filings in the 'USA Board Room Changes' stream reveal a wave of 25+ executive and board transitions, including 12 CEO/CFO appointments/resignations and 10+ director elections/additions, often featuring experienced hires amid mixed Q1 FY2026 earnings with average reported revenue growth of +6% YoY (Klaviyo +28% outlier, FTC Solar -17% low-end) and gross margin expansions in 4/10 reporting firms (Energizer +360bps standout). Declines in volumes/sales hit cyclical sectors (Energizer batteries -6.1%, Primoris Energy -13.8%), but Adjusted EBITDA grew +10% on average where disclosed, driven by organic expansions and acquisitions. Guidance was raised/reaffirmed in 8/12 cases (e.g., AdaptHealth revenue to $3.45-3.52B, Klaviyo to $1.514-1.522B), signaling management confidence post-changes; capital returns strong via $500M+ buybacks (Klaviyo, Emerson). Positive sentiment in 40% of filings tied to continuity hires (Integra Essig return), while neutral/negative in departures without successors (Portillo CFO). Portfolio implications: Healthcare and industrials show leadership stabilization for growth, consumer CFO churn flags execution risks. Overall, transitions lean positive for long-term execution, with near-term catalysts from earnings calls.

35 high priority 35 total filings
· daily

US Merger & Acquisition SEC Filings — May 05, 2026

The 16 filings reveal a surge in SPAC activity with 8 new IPOs, extensions, unit separations, and de-SPAC mergers targeting tech, AI, healthcare, logistics, and biofuels, signaling robust M&A momentum in high-growth sectors amid a May 2026 filing cluster. Key period-over-period trends include Avista Corp's Q1 2026 GAAP net income up 16% YoY to $92M ($1.11/share) and non-GAAP utility earnings up 11% to $91M, though electric margins dipped slightly QoQ; limited other operational comps highlight deal-driven focus over earnings. Critical developments feature Compass Diversified's $292.5M subsidiary sale for deleveraging to <1.0x leverage by June 30, multiple $60-105M SPAC IPOs, and high-value mergers like DMAA-PAGC at $1B EV and Applied Digital's 97%-owned ChronoScale spin-off. Portfolio-level patterns show positive sentiment in 9/16 filings (avg materiality 8.3/10), with SPACs dominating (50% of filings) and M&A completions/announcements in AI/data centers/biofuels, implying investor appetite for tech consolidation despite redemption risks in extensions like Pyrophyte's $1.29M outflow. Capital allocation leans toward deleveraging (CODI) and reinvestment via acquisitions (Exodus $30M, Oncotelic $20M IP), with no dividend/buyback shifts noted. Market implications: heightened takeover premiums and SPAC dry powder could drive 10-20% upside in targets, but monitor redemptions and leverage covenants.

16 high priority 16 total filings
· daily

Nasdaq 100 Stocks SEC Filings — May 04, 2026

Across 30 SEC filings from NASDAQ-100 related entities on May 4, 2026, overarching themes include mixed Q1 2026 financial results with revenue growth in niche players (e.g., OneMeta +4710% YoY, Metallus +10% YoY) offset by declines in established names (Cogent service rev -3.2% YoY, Apple Hospitality net income -11.3% YoY), strong shareholder approvals at annual meetings (Gilead, Intuitive Surgical, Cogent >90% FOR on key proposals), and active capital markets with Meta's $25B debt raise and Genco's $23.50/share tender offer. Portfolio-level trends show margin resilience in some (Cogent EBITDA margin + to 29.3%, Metallus EBITDA +39% YoY) amid operating losses, with REITs like Apple Hospitality and Sun Communities signaling acquisition pipelines and presentations. M&A/SPAC activity is elevated (AParadise merger approval with 19.6M shares redeemed, Genco takeover), while capital allocation favors buybacks/dividends (Apple Hospitality $242.5M remaining, Cogent $0.02 dividend). Neutral 13F filings indicate passive institutional holding, and positive governance updates (board appointments, equity plans) dominate. Implications: Selective growth opportunities in high-flyers, caution on margin pressures, catalysts from conferences and deal closings.

14 high priority 16 medium 30 total filings
· daily

S&P 500 Financials Sector SEC Filings — May 04, 2026

Across 50 SEC filings from May 4, 2026, primarily S&P 500 Financials but spanning insurers, REITs, banks, SPACs, and broader sectors, key themes include robust M&A/SPAC activity (e.g., GNL-Modiv accretive merger, multiple IPO S-1/A amendments), mixed Q1 2026 results with aggregate revenue growth of ~6% YoY in reporting companies (e.g., Berkshire +4.4%, Loews +1.4%, CNA +1.4%) but volatile net income (Berkshire +119% outlier, CNA -23%, Loews -9%), and insurance underwriting pressures (combined ratios worsening ~380bps YoY at CNA/Loews). Capital allocation shows steady dividends (CNA $0.48/share, Superior $0.14/share) amid buybacks (Berkshire $235M treasury stock) and debt reductions (Superior LT debt -8% QoQ). Institutional 13Fs reveal tech-heavy portfolios (e.g., Crystal Rock top Alphabet/Meta, Yahav QQQ semis), signaling conviction in growth sectors. Forward-looking data flags lowered guidance (Norwegian Net Yield -3-5%) and catalysts like Cabaletta data H1/H2 2026. Portfolio-level trends: 8/12 earnings reporters saw revenue +YoY but 6/12 net income declines; M&A premiums average 17% (GNL-Modiv). Implications: Favor accretive deals and strong earners like Berkshire; caution insurers on reserves/loss ratios amid positive BVPS trends.

28 high priority 22 medium 50 total filings